Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 16/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12376524 | 0.92 | LMNA (0.45) | NPC1LMNAMAPTMAPK1RAB9A | |
| SCHEMBL1075947 | 0.90 | LMNA (0.48) | NPC1LMNAMAPTMAPK1RAB9A | |
| SCHEMBL12376551 | 0.86 | NPC1 (0.39) | NPC1LMNAMAPTMAPK1RAB9A | |
| SCHEMBL2282429 | 0.86 | ADORA1 (0.52) | NPC1LMNAMAPTMAPK1RAB9A | |
| SCHEMBL12376489 | 0.85 | ADORA1 (0.56) | NPC1MAPTRAB9AADORA1SLC6A3 | |
| SCHEMBL12376494 | 0.84 | NPC1 (0.42) | NPC1LMNAMAPTMAPK1RAB9A | |
| SCHEMBL12535119 | 0.80 | ADORA1 (0.53) | NPC1LMNAMAPTMAPK1RAB9A | |
| SCHEMBL12376503 | 0.80 | ADORA1 (0.41) | NPC1LMNAMAPTMAPK1RAB9A | |
| SCHEMBL2281823 | 0.79 | MAPT (0.43) | NPC1LMNAMAPTMAPK1RAB9A | |
| SCHEMBL12535087 | 0.78 | ADORA1 (0.43) | NPC1LMNAMAPTMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426602-B2 | Heteroaryl-substituted dicyanopyridines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| US-20110207698-A1 | HETEROARYL-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207698-A1 | HETEROARYL-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE | QDPR, TNNI3, SDHA | NPC1 225/4885LMNA 339/4885MAPT 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.